Related by context. All words. (Click for frequent words.) 88 sodium Injection 86 Genasense R oblimersen 80 DNA RNA Medicines 75 Panzem R 74 anticancer compound 74 oral prodrug 73 2 methoxyestradiol 72 efaproxiral 72 liposomal formulation 72 IRX 2 72 targeted radiotherapeutic 72 PROVENGE sipuleucel T 72 IMiDs ® 71 Personalized Immunotherapy 71 IL# PE#QQR 71 novel VDA molecule 71 PI3K/Akt pathway inhibitor 71 Phase #b/#a clinical 71 SinuNase TM 71 FOLOTYN ® 71 AAG geldanamycin analog 71 catheter occlusion 71 Curaxin CBLC# 71 Tezampanel 70 polysaccharide polymer 70 compound INCB# 70 CTAP# Capsules 70 MAGE A3 ASCI 70 IMiDs R 70 Genasense oblimersen sodium Injection 70 lucinactant 70 PDX pralatrexate 70 alkylating agent 70 virus HCV protease inhibitor 70 TRO# 70 compound PMX # 70 candidate deforolimus 70 Pivotal Phase III 70 SinuNase ™ 70 TLK# 70 BiovaxID TM 70 evaluating picoplatin 70 proprietary polysaccharide 70 lintuzumab SGN 70 LymphoStat B belimumab 70 Telik logo TELINTRA 70 candidate XP# 70 GLP1 INT TM 70 omecamtiv mecarbil formerly 70 non porcine pancreatic 70 MEK Inhibitor 69 pan histone deacetylase 69 arsenic trioxide injection 69 apricitabine ATC 69 metaglidasen 69 paclitaxel Taxol ® 69 SPRYCEL ® 69 5 HT3 antagonist 69 vapreotide acetate 69 mertansine 69 Zorbtive TM 69 generation purine nucleoside 69 Archexin 69 evaluating tivozanib 69 NeuroSTAT ® 69 Completes Patient Enrollment 69 interferon gamma 1b 69 Initiates Enrollment 69 orally administered inhibitor 69 R Saizen R 69 Panzem R NCD 69 PNP inhibitor 69 PEG SN# 69 octreotide acetate 69 ALN PCS 69 Cleviprex TM clevidipine 69 delivers fluocinolone acetonide FA 69 Locteron ® 69 hormone LHRH antagonist 69 XL# anticancer compounds 69 sulfonylhydrazine class 69 non nucleoside inhibitor 69 Vidaza azacitidine 69 HGS ETR2 69 investigational immunotherapy 68 Androxal TM 68 monoclonal antibody conjugated 68 Elagolix 68 Mg Usa 68 oncolytic virus therapies 68 Anturol TM 68 Pivotal Phase 68 HDL Mimetic Peptide 68 topically applied SEPA 68 hypoxia selective 68 MKC# 68 mGluR5 negative 68 Pegloticase 68 PEGylated anti 68 Ophena TM 68 HGS ETR1 mapatumumab 68 oral ridaforolimus 68 sapropterin dihydrochloride 68 LEP ETU 68 LymphoStat B TM 68 Survivin antagonist 68 refractory chronic lymphocytic 68 Romiplostim 68 GAMMAGARD 68 targets Galectin receptors 68 PrevOnco ™ 68 personalized cellular immunotherapy 68 Vidaza ® 68 intranasal formulation 68 CDK cyclin dependent 68 trial evaluating PRX# 68 Xcytrin R 68 inhibitor PPI 68 acetonide FA 68 metastatic castration resistant 68 Initiates Phase II 68 Phase 2b Trial 68 Glufosfamide 68 brand ciclesonide HFA 68 CYT# potent vascular disrupting 68 Vascugel 68 Initiate Clinical Trial 68 Phase IIb clinical trials 68 Safinamide 68 investigational pharmacologically unique 68 IgG1 monoclonal antibody 68 forodesine 68 5 FU leucovorin 68 PEGylated Fab fragment 68 Anturol ® 68 interferon beta 1a infertility 68 docetaxel Taxotere R 68 trastuzumab DM1 T DM1 68 pan HDAC inhibitor 68 Hsp# Inhibitor 68 dasatinib Sprycel ® 68 bucindolol hydrochloride 68 Proellex TM 68 lomitapide 68 systemic anaplastic large 68 hyperphenylalaninemia HPA due 68 PHX# 68 telomerase therapeutic 68 Aflibercept 68 colesevelam HCl 68 Meets Primary Endpoint 67 5 fluorouracil leucovorin 67 docetaxel Taxotere ® 67 NicVAX TM 67 Azedra 67 kidney urologic 67 phase III isavuconazole 67 highly selective inhibitor 67 sorafenib tablets 67 Phase 2b Clinical Trial 67 Cloretazine 67 candidates Azedra TM 67 Randomized Phase 67 alvespimycin 67 Combination REOLYSIN R 67 hyaluronidase enzyme 67 erlotinib Tarceva ® 67 oral picoplatin 67 memantine HCl 67 PROVENGE ® 67 CK # novel 67 ATPace TM 67 ALN HPN 67 induced macular edema 67 IMA# 67 Marqibo TM 67 investigational humanized monoclonal antibody 67 gefitinib Iressa 67 FOLFOX6 chemotherapy regimen 67 topical gel formulation 67 reslizumab 67 IAP inhibitor 67 methylnaltrexone bromide 67 PSMA ADC 67 systemic RNAi therapeutic 67 Receives Orphan Drug Designation 67 PEGylated interferon 67 pralatrexate injection folate analogue 67 ADP receptor antagonist 67 oral nucleoside analogue 67 acyclovir Lauriad R 67 histone deacetylase HDAC inhibitor 67 AEG# 67 Crofelemer budesonide foam 67 Apoptone 67 small molecule Hedgehog 67 P#X# antagonist 67 Cannabinor 67 ThermoDox ® clinical 67 evaluating bafetinib 67 selective androgen receptor modulator 67 systemically administered 67 telomerase inhibitor drug 67 Inhalation Aerosol 67 Intravitreal 67 ZOLINZA 67 HDAC Inhibitor 67 ONCONASE R 67 biomodulator 67 essential thrombocythemia ET 67 TOCOSOL Camptothecin 67 TBC# 67 IMiDs 67 phase IIb clinical 67 Ovitrelle R Serostim 67 Quinamed 67 xanthine oxidase inhibitor 67 Bazedoxifene 67 MEK inhibitor 67 R metformin Concor 67 Granted Orphan Drug 67 molecular imaging radiopharmaceutical 67 tiapamil 67 Aganocide 67 Kamada AAT 67 ATL# [001] 67 sodium glucose cotransporter 67 Cloretazine ® 67 ® lenalidomide 67 Inhalation Solution 67 Vicriviroc 67 Cetrorelix 67 JZP 67 Initiates Phase III 67 bortezomib Velcade 67 corticotropin injection 67 FUSILEV enhances 67 IMiDs ® compound 67 Xanafide 67 MEK inhibitor RDEA# 67 candidate TNFerade biologic 67 MGd 67 INCB# [001] 66 Perflubutane Polymer Microspheres 66 R bisoprolol Euthyrox 66 oxybutynin ATD TM 66 MKC# MT 66 BENLYSTA ® 66 combines bupropion 66 Annamycin 66 Proxinium TM 66 TNF Tumor Necrosis Factor 66 TRIOLEX HE# APOPTONE HE# 66 refractory gout 66 ongoing Phase 1b 66 CORT # 66 markets HP Acthar 66 ferric citrate 66 Randomized Double blind 66 dextofisopam 66 urocortin 2 66 drug ISA# 66 novel DACH platinum 66 novel synthetic PEGylated 66 Novel Oral 66 Presents Preclinical Data 66 vinca alkaloid 66 sapacitabine CYC# 66 beta 1a 66 Xeloda ® 66 TNFerade TM 66 YONDELIS 66 peptidic compound 66 CEQ# 66 PROSTASCINT R 66 XYOTAX TM 66 investigational monoclonal antibody 66 nasal calcitonin product 66 mitogen activated ERK kinase 66 ruxolitinib 66 Initiates Clinical Trial 66 Investigational Oral 66 Liprotamase 66 SPL# Gel vaginal microbicide 66 RiVax 66 accumulate preferentially 66 Cand5 66 successfully commercialize Iluvien 66 candidate Gencaro TM 66 vinorelbine tartrate 66 Oral Fingolimod 66 Phase 1b clinical trials 66 Parathyroid Hormone 66 Achieves Primary Endpoint 66 lexidronam injection 66 Begins Dosing 66 Empatic ™ 66 ApoB SNALP 66 Omacetaxine 66 ATRA IV 66 R#/MEM # 66 Peginterferon alfa 2b 66 Darinaparsin 66 Phase IIb Trial 66 cysteamine bitartrate 66 selective modulator 66 Exherin 66 Alocrest 66 Phase III Clinical Trial 66 Temsirolimus 66 Zemiva TM 66 mGluR5 NAM 66 Vidaza R 66 sulodexide 66 lead molecular radiotherapeutic 66 small molecule defensin 66 product candidate Lpathomab 66 Squalamine 66 octreotide implant 66 EVIZON TM squalamine lactate 66 VEGFR2 inhibitor 66 OvaRex ® MAb 66 Celacade TM technology 66 Exherin TM 66 GVAX ® 66 PDE4 inhibitor 66 Serostim ® 66 huC# DM4 66 PANVAC VF 66 EOquin TM 66 GVAX R 66 oxymorphone ER 66 #ME# 66 BXT # 66 trastuzumab Herceptin R 66 elotuzumab 66 Initiate Phase 66 Panzem NCD 66 LibiGel ® 66 AKT inhibitor 66 next generation URAT1 66 ThermoDox R 66 ocular formulation 66 pharmacologically active isomer 66 Pruvel TM 66 Fludara ® 66 Gel repository corticotropin injection 66 recurrent metastatic ovarian cancer 66 corticosteroid dexamethasone 66 treat chronic sinusitis 66 Bezielle 66 fosbretabulin 66 Oracea TM 66 Dose Ranging Study 66 Preclinical studies suggest 66 Phase Ib study 66 nucleotide analogue 66 Presents Preclinical 66 Dasatinib 66 TELINTRA R 66 SUPPRELIN R LA 66 Solazed TM 66 CCX# 66 thalidomide Thalomid 66 metastatic colorectal 66 BEMA Granisetron 66 R sorafenib tablets 66 Xelox 66 Metastatic Melanoma 65 VitiGam 65 Bosutinib 65 antibody MAb 65 Vicinium TM 65 TRANSDUR ® 65 Prostate AdenoCarcinoma Treatment 65 generation Hsp# inhibitor 65 Shows Statistically Significant 65 WX UK1 65 imexon 65 PRTX 65 CYP#A# CYP#D# 65 INSPIRE Trial Phase III 65 Biolimus A9 65 Lenocta TM 65 dasatinib Sprycel 65 Perforomist ™ Inhalation Solution 65 cancer neuroendocrine tumor 65 ELACYT 65 Complicated Skin 65 phase IIb trial 65 MAXY G# 65 modified glutathione analog 65 Vascular Disrupting Agent 65 eniluracil 65 defensin mimetic antibiotic 65 Lenocta 65 drug GAP #B# 65 Oral Calcitonin 65 CRMD# 65 Intravenous Human 65 CD# CEA 65 Gemzar ® 65 dihydrochloride 65 gemcitabine Gemzar ® 65 orally bioavailable mimics 65 Solazed ™ 65 OMNARIS HFA 65 Phase 2a Clinical Trial 65 OAB overactive bladder 65 candidate brentuximab vedotin 65 mesylate tablets 65 SUCCEED trial 65 evaluating satraplatin 65 FDA APPROVES 65 intravesical infusion therapy 65 Submits Response 65 Initiates Clinical 65 PLK1 SNALP 65 torezolid phosphate 65 Azedra TM 65 TPI ASM8 65 ALVESCO ® 65 Hormone Refractory Prostate Cancer 65 Pimavanserin 65 candidates Azedra 65 Onalta ™ 65 adjuvant GIST 65 orally inhaled 65 BrachySil TM 65 cardiometabolic diseases Glucophage 65 Injectable Suspension 65 PSN# [002] 65 ARRY # 65 granted Ortec 65 5 Fluorouracil 65 Study Evaluating 65 developing Zerenex TM 65 autologous cellular immunotherapy 65 PRT# 65 PKC# 65 TELINTRA 65 Mycophenolate Mofetil 65 investigational oral hepatitis C 65 class anticancer quinolone 65 CINQUIL 65 CCR9 antagonist 65 QuadraSphere 65 aldehyde dehydrogenase ALDH2 deficiency 65 Interferon beta 1a 65 substantially excreted 65 orBec R oral beclomethasone 65 CB2 selective receptor agonist 65 GW# [003] 65 Sapacitabine 65 granisetron formulated 65 cisplatin gemcitabine 65 rhIGF-I/rhIGFBP-3 65 Lisofylline LSF 65 Foradil Aerolizer 65 ISTODAX 65 Hedgehog Pathway Inhibitor 65 VIVITROL ® 65 nilotinib Tasigna ® 65 immunotherapeutic agent 65 Protexia ® 65 overactive bladder VANTAS R 65 ancrod 65 RELOVAIR ™ 65 Zerenex 65 Selective Electrochemical Tumor Ablation 65 S1P antibody 65 Chemophase 65 Bendamustine 65 Pemetrexed 65 candidate epratuzumab 65 squalamine 65 Cotara R 65 compound ISA# 65 Orally administered 65 Phase III Pivotal 65 topically administered 65 Iluvien ® 65 demonstrated antitumor activity 65 agonistic human 65 PrevOnco 65 HuMax EGFr 65 drug pipeline TAFA# 65 Entereg R 65 Alfacell proprietary ribonuclease 65 sitaxsentan 65 R lenalidomide 65 alfa 2a 65 MyVax R 65 HMG CoA reductase inhibitors 65 Pruvel ™ 65 nucleotide analog 65 pioglitazone HCl 65 developing Zerenex ferric 65 Prodarsan R 65 luteinizing hormone releasing 65 HGS ETR1 65 candidate EFAPROXYN TM 65 cetuximab Erbitux 65 Spiegelmer ® 65 pseudobulbar affect PBA 65 Ticagrelor 65 Eniluracil 65 lapatinib Tykerb 65 vidofludimus 65 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 65 cetrorelix pamoate 65 Tovaxin TM 65 ALN TTR# 65 phenyl salicylate methylene blue 65 ALV# 65 Voreloxin 65 Regeneron Pharma 65 DPX Survivac 65 oral ferric iron 65 Zybrestat 65 candidates bavituximab 65 topoisomerase II inhibitor 65 Epratuzumab 65 verteporfin 65 subsidiaries visit http:/www.apricusbio.com 65 Microplasmin 65 Motesanib 65 Recombinant Human 65 investigational antiplatelet agent 65 including eniluracil ADH 65 Patients Treated With 65 Fodosine 65 Abiraterone acetate 65 ara C 65 Intravenous CP 65 novel immunomodulatory 65 Submits Biologics License Application 65 diagnostic radiopharmaceutical 65 sarcoma melanoma 65 sodium thiosulfate STS 65 please visit www.advaxis.com 65 cetuximab Erbitux R 65 CoFactor 65 HCV protease inhibitor 65 HepeX B TM 65 huN# DM1 65 samarium Sm 65 lenalidomide Revlimid R 65 Besivance 65 Xyfid TM 65 Talabostat 65 protein tyrosine phosphatase 1B 64 VAPRISOL 64 Methylnaltrexone 64 Testosterone MDTS ® 64 oral rivaroxaban 64 MGCD# MGCD# [001] 64 Triapine R 64 candidate Lovaxin C 64 Myolimus 64 Phase Ib II 64 Phase Ib clinical trials 64 therapeutically inactive prodrug 64 treat male hypogonadism 64 Pharmacokinetics PK 64 Phase #b/#a trial 64 CIMZIA R 64 mTOR mammalian target 64 Panzem 64 Phase IIb Clinical Trial 64 % uracil topical 64 Neo Kidney Augment 64 rNAPc2 64 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 64 dependent kinase inhibitor 64 mapatumumab 64 Taxotere docetaxel 64 registrational trial 64 Zalypsis 64 5 lipoxygenase inhibitor 64 NEBIDO R 64 somatropin Kuvan R 64 Diamyd R 64 EDEMA3 trial 64 JAK1 64 Demonstrates Significant 64 NUVIGIL ® 64 oral deforolimus 64 Dapagliflozin 64 Aganocide ® 64 Receives Approvable Letter 64 BCR ABL inhibitor 64 ALN TTR 64 R memantine HCl 64 DNA demethylating agent 64 Denufosol 64 Silodosin 64 lesinurad 64 ZEVALIN ® 64 QUADRAMET R 64 seliciclib CYC# 64 refractory cutaneous T 64 PF # [002] 64 Xcellerated T Cells 64 Taxotere chemotherapy 64 oral beclomethasone dipropionate 64 Phase #/#a trial 64 Receives Orphan Drug 64 norepinephrine reuptake inhibitor 64 orally inhaled migraine 64 histamine dihydrochloride 64 Opterone R 64 Mg Uk 64 Resten NG 64 Announces Tentative Approval 64 systemic immunosuppressive drugs 64 Vildagliptin 64 HP Acthar Gel repository 64 Factor VIIa 64 Dacogen injection 64 brivaracetam 64 custirsen 64 Hematide TM 64 Tasimelteon 64 Vitrasert R 64 dihydrochloride Tablets 64 Hematide ™ 64 EnteroMedics proprietary neuroblocking technology 64 FUSILEV ® 64 Plicera 64 familial amyloidotic polyneuropathy FAP 64 Civacir 64 Nexavar sorafenib tablets 64 Dyloject TM 64 developing Bicifadine serotonin 64 HuMax TAC 64 Friedreich Ataxia FRDA 64 thromboxane A2 64 novel histone deacetylase 64 Immunotherapeutic 64 microsphere therapy 64 myelodysplastic myeloproliferative diseases 64 BioMarck 64 Phase 2b clinical trials 64 Phase III ADT 64 Angiotensin Converting Enzyme 64 compound perifosine 64 HQK 64 cortisol synthesis 64 tubulin inhibitor 64 Tanespimycin 64 novel synthetic peptide 64 Genasense ® 64 orBec 64 nucleoside reverse transcriptase inhibitor 64 JAK2 Inhibitor 64 Rigel R# 64 markets COLAZAL 64 Long acting beta2 64 ABL inhibitor 64 OMP #R# 64 CR# vcMMAE 64 nucleoside analog 64 irinotecan doxorubicin oxaliplatin paclitaxel 64 Enzastaurin 64 HCV NS5B polymerase 64 EFAPROXYN 64 Phase 2a clinical 64 specific lectin receptors 64 oxaliplatin Eloxatin 64 Fondaparinux 64 non nucleoside HCV 64 CCR5 mAb 64 PROGENSA R 64 acid phosphatase PAP 64 RANK Ligand inhibitor 64 eprotirome 64 Phase IIb trials 64 brivanib 64 ANCHOR trial 64 Tesetaxel 64 Cyclooxygenase Inhibiting Nitric Oxide 64 By JENNIFER LEARN 64 Luveris R Ovidrel R 64 faropenem medoxomil 64 hypoxia activated prodrug 64 Albuferon TM 64 humanized therapeutic 64 ZADAXIN ® 64 Tarceva TM 64 ospemifene 64 Pertuzumab 64 BrachySil ™ 64 HEPLISAV TM 64 Aganocide R 64 delivery polymer matrix 64 #HT# 64 IMiD 64 inhaled formulation 64 GTC recombinant human 64 ALTROPANE R 64 MIVI III 64 apoptosis proteins 64 TransVax tm 64 gemcitabine cisplatin 64 alpha folate receptor 64 novel emulsion formulation 64 R#/MEM 64 Allovectin 7 64 developing ACAPODENE 64 Urocortin 2 64 FDA Approvable Letter 64 VALSTAR TM 64 Maribavir 64 investigational protease inhibitor 64 plus dacarbazine 64 long acting muscarinic 64 Receptor Agonist 64 Aplidin R 64 PRN FDA Approves 64 REVLIMID lenalidomide 64 recombinant subunit vaccine 64 AZILECT R 64 candidate MyVax 64 metformin hydrochloride 64 CD4 monoclonal antibody 64 Granulocyte Colony Stimulating Factor 64 Pivotal Trial 64 Protease Inhibitor 64 aurora kinase 64 proprietary intravenous formulation 64 Amplimexon 64 Completes Enrollment 64 vorinostat 64 Sprycel dasatinib 64 R bendamustine hydrochloride 64 ritonavir boosted danoprevir 64 HuLuc# 64 TO AVOID PREGNANCY WHILE 64 cromolyn sodium 64 Patient Enrollment 64 candidate CRLX# 64 Bicifadine 64 CXB# 64 alefacept 64 HDL Selective Delipidation 64 Polymer Microspheres 64 Soriatane 64 dose escalation clinical 64 Interferon beta 1b 64 AFREZZA TM 64 recurrent metastatic 64 PEG irinotecan 64 Submits NDA 64 cutaneous T 64 incyclinide 64 Fx #A 64 Febuxostat 64 Prolongs Survival 64 multi kinase inhibitor 64 telaprevir dosed 64 Virulizin ® 64 velafermin belinostat 64 Monotherapy 64 Alfimeprase 64 Soliris eculizumab 64 neratinib 64 IAP inhibitors 64 IMPDH inhibitor 64 Altera Nebulizer System 64 oral gallium 64 sorafenib Nexavar 64 EGS# 64 Presents Positive 64 Serdaxin ® 64 XL# XL# XL# XL# 64 armodafinil Tablets C 64 oritavancin semi 64 aripiprazole Abilify 64 individualized cellular immunotherapy 64 Degarelix 64 Phase 2a Trial 64 mocetinostat MGCD# 64 Locked Nucleic Acid LNA 64 Varespladib 64 NDA Submission 64 DG# compounds targeting 64 liposome encapsulated 64 BrachySil 64 Kit CD# positive 64 dextromethorphan quinidine 64 FACTIVE R gemifloxacin 64 Traficet EN 64 candidate Zenvia 64 Tramiprosate ALZHEMED TM 64 MKC# MKC# PP 64 CIMZIA TM 64 targeted antifolate 64 Sanvar R 64 leading oral taxane 64 Seliciclib 64 Investigational Compound 64 metastatic castrate resistant 64 GMX# 64 Tyrima 64 iobenguane 64 TLR9 agonist 63 dimebon latrepirdine 63 OHR/AVR# 63 histone deacetylase inhibitor 63 oral isotype selective HDAC 63 Eltrombopag 63 UPLYSO 63 evaluating Actimmune 63 TAFA# 63 Dose Escalation 63 HCV protease 63 Androxal ® 63 recurrent glioblastoma multiforme 63 THR beta agonist 63 Budesonide foam crofelemer 63 JAK inhibitor 63 Muraglitazar 63 severe hypercholesterolemia 63 miconazole Lauriad R 63 Pyridorin 63 Ixempra 63 metabolic disorders Saizen R 63 Elotuzumab 63 KNS # 63 Antiviral Activity 63 GALNS 63 limiting toxicity DLT 63 REG1 Anticoagulation System 63 TKM ApoB 63 serotonin norepinephrine reuptake inhibitor 63 Aztreonam 63 CIP Fenofibrate 63 BIM #A# 63 J Am Coll 63 CD3 monoclonal antibody 63 Aeolus Pharmaceuticals Announces 63 sunitinib Sutent ® 63 bevacizumab Avastin ® 63 acadesine 63 Clinical Trial Evaluating 63 Atripla combines 63 Liposomal 63 ® pioglitazone HCl 63 lymphoid malignancies 63 Topotecan 63 SIMCOR 63 delta opioid receptor 63 2 inhibitor CYT# 63 AERx ® 63 REG1 63 Zoraxel TM 63 CIMZIA ™ 63 Nexavar sorafenib 63 fluoropyrimidine 63 Zoraxel 63 product platforms AZX# 63 CINOD 63 selective A2A adenosine receptor 63 HGS# 63 teriflunomide 63 LE SN# 63 motexafin gadolinium Injection 63 Qutenza TM 63 ABILIFY ® 63 Kuvan TM sapropterin 63 phase IIb study 63 Poly ICLC 63 generation URAT1 inhibitor 63 JAK2 inhibitor 63 Phase 2a trial 63 Ophena 63 Brentuximab Vedotin SGN 63 BRIM2 63 Ranolazine 63 occlusion PAO 63 Amigal TM 63 candidate NGX 63 Irinotecan 63 CINTREDEKIN BESUDOTOX 63 Provenge sipuleucel T 63 signal transduction inhibitor 63 rxRNA 63 ProLindac TM 63 PS# [001] 63 R roscovitine CDK cyclin 63 Drug Candidate 63 ACTEMRA TM 63 HCV polymerase inhibitors 63 herpetic keratitis 63 fallopian tube cancers 63 Sudhir Agrawal D.Phil 63 HCl PEPCID ® famotidine 63 Sym# 63 MTP inhibitor 63 NU# direct 63 Camptosar ® 63 palifermin 63 brain metastases originating 63 reduce serum phosphate 63 ACAPODENE 63 epoetin alpha 63 investigational oral inhibitor 63 docetaxel Taxotere 63 Glycopyrrolate 63 midstage clinical 63 adalimumab Humira 63 Mylan Receives Approval 63 Vidofludimus 63 vosaroxin 63 OPAXIO TM 63 Fosphenytoin 63 candesartan cilexetil 63 Onconase 63 Antitumor Activity 63 initiated Phase 1b 63 Hodgkin lymphoma HL 63 PRNewswire FirstCall Genta Incorporated 63 cyclobenzaprine hydrochloride extended 63 Receives Fast Track 63 Pathway Inhibitor 63 candidate AQ4N 63 Corlux 63 BENICAR 63 Solution XOPENEX HFA 63 AVASTIN 63 HepaMate 63 hA# 63 See CLINICAL PHARMACOLOGY 63 assessing T DM1 63 R vancomycin hydrochloride 63 SomatoKine 63 alvimopan 63 erlotinib Tarceva 63 Moxifloxacin 63 topical non steroidal 63 RECOTHROM R 63 rHuPH# enzyme 63 neuronal nicotinic receptor NNR 63 uricase 63 thetreatment 63 Loceryl ® 63 Phase Ib IIa 63 lamotrigine Lamictal 63 selective adenosine 63 forodesine hydrochloride 63 Myelodysplastic Syndrome MDS 63 inhalation aerosol 63 r hGH 63 Protexia R 63 alkylating 63 Camptosar ® irinotecan 63 hoFH 63 DexaSite 63 rivastigmine Exelon 63 BCG refractory carcinoma 63 albiglutide 63 Factor Receptor 63 pancreatic prostate 63 R sipuleucel T 63 Cytogen marketed 63 Randomized Phase II 63 Inc. Nasdaq CYCC 63 treat opioid induced 63 metastatic hormone refractory 63 metastatic malignant 63 Neulasta R 63 CBLC# 63 receptor tyrosine kinase inhibitor 63 formoterol fumarate 63 Inc. NASDAQ AEZS 63 Aurora Kinase 63 include PLX IBD 63 treat refractory angina 63 abacavir sulfate lamivudine 63 phase IIb III 63 Naive Patients 63 humanized anti 63 nalbuphine ER 63 gemcitabine Gemzar 63 Demonstrates Sustained 63 HCV RNA polymerase 63 Nasdaq GNTA 63 Phase IIa Clinical Trial 63 II Clinical Trial 63 chemotherapy induced neutropenia 63 Gleevec imatinib mesylate 63 LungAlert TM 63 opioid induced bowel dysfunction 63 standard chemotherapy regimen 63 personalized dendritic 63 Pirfenidone 63 diarrhea predominant irritable 63 MOVIPREP R